MedTrace Logo

Acute Impact of Non-Sugar Sweeteners (Sucralose and Aspartame)

NCT07506564 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-04-01

No results posted yet for this study

Summary

The major purpose of this research project is to learn if consuming artificial sweeteners have any impact on glucose levels in adults at high risk for developing type 2 diabetes. People may be at risk for diabetes if you are a middle-aged or older adult. Briefly, the full study is 3 weeks long with 3 controlled feeding visits. Which means participants will eat all of the food and drinks that we provide to them for breakfast. Participants will come to the lab in the morning to eat breakfast, and we will monitor changes in blood glucose over a 2 hour period. Participants will be randomized into 1 of 3 groups: 1 group will receive aspartame (Equal), 1 group will receive sucralose (Splenda), and 1 group will receive no artificial sweeteners. Participants will experience a different group each visit, with about 7 days between each visit. We will be examining if consuming artificial sweeteners has any impact on glucose levels.

Conditions

Interventions

OTHER

non-sugar sweeteners - Sucralose

Participants will be given 2.5 mg/kg of body weight of sucralose

OTHER

non-sugar sweetener - aspartame

Participants will receive 25 mg/kg body weight of aspartame

OTHER

Non-sugar sweetener - control

Participants will receive 340 mg of dextrose

Sponsors & Collaborators

  • Virginia Polytechnic Institute and State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2025-03-05
Completion
2025-05-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07506564 on ClinicalTrials.gov